Akero Therapeutics Inc (AKRO)
19.74
+0.81
(+4.28%)
USD |
NASDAQ |
Apr 26, 16:00
19.72
-0.02
(-0.13%)
After-Hours: 20:00
Akero Therapeutics Cash from Operations (Quarterly): -48.63M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -48.63M |
| September 30, 2023 | -49.72M |
| June 30, 2023 | -22.39M |
| March 31, 2023 | -24.63M |
| December 31, 2022 | -25.51M |
| September 30, 2022 | -24.62M |
| June 30, 2022 | -19.51M |
| March 31, 2022 | -22.88M |
| December 31, 2021 | -26.70M |
| September 30, 2021 | -14.61M |
| June 30, 2021 | -20.03M |
| March 31, 2021 | -18.35M |
| Date | Value |
|---|---|
| December 31, 2020 | -23.40M |
| September 30, 2020 | -13.51M |
| June 30, 2020 | -22.58M |
| March 31, 2020 | -11.32M |
| December 31, 2019 | -11.65M |
| September 30, 2019 | -13.21M |
| June 30, 2019 | -5.322M |
| March 31, 2019 | -5.444M |
| December 31, 2018 | -2.075M |
| September 30, 2018 | -1.961M |
| June 30, 2018 | -0.251M |
| March 31, 2018 | -0.338M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-49.72M
Minimum
Sep 2023
-5.322M
Maximum
Jun 2019
-22.03M
Average
-22.39M
Median
Jun 2023
Cash from Operations (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -79.93M |
| 89bio Inc | -34.29M |
| Viking Therapeutics Inc | -6.134M |
| Eli Lilly and Co | -311.90M |
| Ionis Pharmaceuticals Inc | 32.86M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 12.79M |
| Cash from Financing (Quarterly) | 0.502M |
| Free Cash Flow | -145.37M |
| Free Cash Flow Per Share (Quarterly) | -0.8722 |
| Free Cash Flow Yield | -14.02% |